• 1
    Marty M, Pouillart P, School S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990; 322: 816821.
  • 2
    Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993; 118: 407413.
  • 3
    Cassileth PA, Lusk EJ, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med. 1983; 143: 13471349.
  • 4
    Markman M, Sheidler V, Ettinger DS, et al. Antiemetic efficacy of dexamethasone—randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984; 311: 549552.
  • 5
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 33123322.
  • 6
    ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997; 15: 21832193.
  • 7
    Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001; 81: 206212.
  • 8
    Markman M, Kennedy A, Webster K, et al. Phase II trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000; 78: 369372.
  • 9
    Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001; 82: 323328.
  • 10
    Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001; 83: 257262.
  • 11
    Mitchell SK, Carson LF, Judson P, et al. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer. 2005; 15: 793798.
  • 12
    Herzog TJ, Powell MA, Rader JS, et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006; 103: 637641.
  • 13
    Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004; 95: 564569.
  • 14
    O'Malley DM, Azodi M, Makkenchery A, et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2005; 98: 242248.
  • 15
    Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther. 2004; 11: 501506.
  • 16
    Rustin GJS, Bast RJJr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluations of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004; 10: 39193926.
  • 17
    Vergote I, Rustin GJS, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (Ovarian Cancer). J Natl Cancer Inst. 2000; 92: 15341535.